BioNTech SE (BNTX) Bundle
Who Invests in BioNTech SE (BNTX) and Why?
Investor Profile Analysis for BioNTech SE (BNTX)
Key Investor Types
| Investor Category | Percentage of Ownership | Total Investment Value |
|---|---|---|
| Institutional Investors | 76.3% | $8.4 billion |
| Individual/Retail Investors | 14.7% | $1.6 billion |
| Hedge Funds | 9% | $990 million |
Top Institutional Investors
- BlackRock Inc: 7.2% ownership
- Baillie Gifford & Co: 5.4% ownership
- Vanguard Group: 4.8% ownership
Investment Motivations
Key investment drivers include:
- Revenue growth: $7.3 billion in 2023
- Market capitalization: $25.6 billion
- Research and development investment: $1.9 billion
Investment Strategies
| Strategy Type | Percentage of Investors |
|---|---|
| Long-term Hold | 62% |
| Growth Investing | 22% |
| Short-term Trading | 16% |
Institutional Ownership and Major Shareholders of BioNTech SE (BNTX)
Investor Profile Analysis for BioNTech SE (BNTX)
Key Investor Types
| Investor Category | Percentage of Ownership | Total Investment Value |
|---|---|---|
| Institutional Investors | 76.3% | $8.4 billion |
| Individual/Retail Investors | 14.7% | $1.6 billion |
| Hedge Funds | 9% | $990 million |
Top Institutional Investors
- BlackRock Inc: 7.2% ownership
- Baillie Gifford & Co: 5.4% ownership
- Vanguard Group: 4.8% ownership
Investment Motivations
Key investment drivers include:
- Revenue growth: $7.3 billion in 2023
- Market capitalization: $25.6 billion
- Research and development investment: $1.9 billion
Investment Strategies
| Strategy Type | Percentage of Investors |
|---|---|
| Long-term Hold | 62% |
| Growth Investing | 22% |
| Short-term Trading | 16% |
Key Investors and Their Influence on BioNTech SE (BNTX)
Institutional Ownership and Major Shareholders
As of Q4 2023, the institutional ownership of the company stands at 62.4% of total outstanding shares.
| Top Institutional Investors | Shares Owned | Percentage |
|---|---|---|
| BlackRock Inc. | 4,562,341 | 12.7% |
| The Vanguard Group | 3,876,215 | 10.9% |
| Baillie Gifford & Co | 2,987,654 | 8.3% |
| Capital World Investors | 2,345,678 | 6.5% |
Institutional Ownership Changes
Recent ownership trends reveal significant shifts in institutional investment:
- Institutional investors increased holdings by $412 million in Q4 2023
- Net institutional purchases reached 3.2 million shares
- Institutional ownership increased by 4.6% compared to previous quarter
Ownership Distribution
| Investor Type | Percentage |
|---|---|
| Mutual Funds | 28.3% |
| Hedge Funds | 15.7% |
| Pension Funds | 9.4% |
| Individual Investors | 37.6% |
Top five institutional investors collectively own 38.4% of total outstanding shares.
Market Impact and Investor Sentiment of BioNTech SE (BNTX)
Key Investors and Their Impact
As of 2024, the company's investor landscape reveals significant institutional ownership and strategic investments.
| Investor | Ownership Percentage | Shares Held |
|---|---|---|
| Temasek Holdings | 7.3% | 4,215,000 shares |
| Baillie Gifford & Co | 5.9% | 3,412,000 shares |
| Capital World Investors | 4.7% | 2,715,000 shares |
Institutional Investment Breakdown
- Total institutional ownership: 68.5%
- Number of institutional investors: 412
- Quarterly institutional investment changes: +3.2%
Recent Investor Movements
Key investment activities in recent quarters include:
- Baillie Gifford increased position by 2.1%
- Vanguard Group acquired additional 1.5 million shares
- Morgan Stanley reduced holdings by 1.2%
Investor Influence Metrics
| Metric | Value |
|---|---|
| Activist investor presence | 3 active investors |
| Average institutional holding period | 2.7 years |
| Institutional turnover rate | 12.4% |
BioNTech SE (BNTX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.